Embed Size (px)
Citation preview
LEADERS IN MED-TECH COMMERCIALIZATIONFOUNDED 2008
THAT
STRATEGICALLY P R O D U C I N G R E S U L T S
I M P A C T G R O W T H
BUSINESS DEVELOPMENTMarket Research & ModelsBusiness PlansInvestor Materials
CUSTOMER REQUIREMENTSPrimary Market ResearchUser Needs AssessmentKOL Identification & Outreach
CLINICAL DEVELOPMENTClinical StrategyClinical Study Design & SetupReview of Clinical Documents
REIMBURSEMENT STRATEGIESMarket Access LandscapeStakeholder ResearchOptimization of Market Access Strategy
BRANDINGMessaging & PositioningBrand Identity & Guidelines
NAMINGCompany, Product & TechnologyLogo Development
CLINICAL MARKETINGPatient Recruitment MaterialsSAB Management
PUBLICATIONSWhite PapersCase ReviewsPosters & PresentationsClinical Manuscripts
WEBSITESCreative ConceptsCopy DevelopmentProject Management
LAUNCH PLANNINGCommercialization Plans Cross-functional Management
MARKETING COLLATERALBrochures Animation, Video & IllustrationsInfographicsSales Sheets
TRAININGSales, Distributor & Physician
EVENTSBooth Design & GraphicsEvent PlanningConference Management
COMMUNICATIONSAdvertisingPress Releases
GROWTHE COMPANY
MARKETTHE PRODUCT
NURTURETHE CONCEPT
Develop marketing strategies to build a
strong foundation for the company and product
Prepare the company for commercialization
Educate the market and build awareness
to impact growth
S P R I G | 1
OUR SERVICESFrom upstream strategy to downstream commercial execution, we work with clients on all
aspects of the marketing spectrum.
MARKETING • BUSINESS DEVELOPMENT • ENGINEERING • SALES • CLINICAL
S P R I G | 2
OUR LOCATIONSStrategically located in med-tech hubs across the world, we have the functional
expertise and industry knowledge to help you grow your business.
OUR TEAMSPRIG delivers a team, not just a PowerPoint deck. We have extensive
healthcare industry experience that leverages functional backgrounds in:
California:
Bay Area
Orange County
Minneapolis
Chicago
Boston
Israel
Vancouver
General Surgery
Electrophysiology
Interventional Pulmonology
Vascular/ Hemodialysis Access
Robotics
Hernia Repair
Renal Failure
Diabetes
Endovascular: Arterial & Venous
Aesthetics
Cardiac Surgery
Remote Patient Monitoring
Prenatal Diagnostics
Women’s Health
Heart Failure
Interventional Radiology
Ophthalmology
Neuromodulation
Digital Health
Structural Heart
Molecular Diagnostics
Renal Denervation
Reprocessing
Orthopedics
Minimally Invasive Surgery
Interventional Cardiology
S P R I G | 3
OUR EXPERTISESPRIG has experience across a broad range of therapeutic categories. Our industry
knowledge ensures a quick ramp-up and allows us to add immediate value.
ACCESS CLOSURE * • ANALY T ICS 4 L I F E • APAMA MED ICAL • ATHEROMED*
AUTONOMIC TECHNOLOGIES, INC. • BIOSENSORS • BLUEGRASS VASCULAR • CARDIOKINETIXCLEARSIDE BIOMEDICAL • CORINDUS • CORVIA MEDICAL • COVIDIEN* • DATUM DENTAL EBR SYSTEMS • EDWARDS LIFESCIENCES • ELIXIR • ENDOTRONIX • EPIEP FRACTYL LABORATORIES • HEARTFLOW • HOTSPUR* • ICS • INFOBIONIC • INSIGHTRA MEDICAL KALILA MEDICAL* • LAMINATE MEDICAL • MAYA MEDICAL* • MEDTRONIC • NANOSPHERE NEURAVI • NEXSTIM • OMADA HEALTH • OR SAFETY • PELVALON • PULMONX • RAD BIOMEDRDD PHARMA • RESPICARDIA • SAPHEON* • SHIFAMED • S IGHT SCIENCESSPECTRANETICS • STERILMED • TRYTON MEDICAL • TYTOCARE • VOLCANO*
*Acquired
OUR CLIENTSSPRIG is proud to have strong on-going relationships with clients in
the US, Europe, Israel, and Asia. Below is a partial list of our clients.
S P R I G | 4
SPRIG was a huge part of our success that
led to our recent acquisition.”
Gary McCord
Former VP New Business Development, Sapheon*
In our business, speed to market is everything.
In selecting SPRIG, we found a partner that
can meet our marketing needs in a manner
consistent with which we operate.”
Amr Salahieh
President & CEO, Shifamed LLC
We retained SPRIG early in our company’s
development, during our first clinical studies
when we were engaging new partners
and preparing for commercialization.
SPRIG’s ability to translate complex clinical
information into impactful and appropriate
messaging across a variety of marketing
materials was essential to our early success.”
Aaron Kaplan, MD
Founder, Tryton Medical
I have many urgent needs... I essentially need
an outsourced marketing department, or parts
of one, that allows me to receive ‘on-demand’
marketing expertise when and where I need it.”
Jim Clifton
COO, Bluegrass Vascular Technologies *Acquired by Covidien in August 2014
S P R I G | 5
IN THEIR OWN WORDS Quotes from Our Clients
Improving Heart Health
NURTURE THE CONCEPT• BR ANDING •
A brand defines who you are and
builds your value proposition.
What is YOUR story? At SPRIG,
we believe a thoughtfully chosen
name and logo design improve
the brand experience and
enhance your key messages.
S P R I G | 6
IMPROVE THE LIVES OF YOUR SEVERE EMPHYSEMA PATIENTS
We IDENTIFIED patient’s needs.
We CHALLENGED the status quo.
We REDEFINED the treatment
of lung disease.
We INVITE you to advance the care
of your patients, using a minimally
invasive device that has been
used in over 10,000 patients and
is currently in use in Europe, Asia,
Australia, and South America.
Pulmonx_Liberate-Phy_Brochure-PRESS.indd 8-9 4/24/15 10:42 AM
INITIAL ELIGIBILITY SCREENINGSigned Informed ConsentPhysical Examination & Medical HistoryLung Function Testing:
• Spirometry• Body Plethysmography• DLCO
High Resolution CT (HRCT) Assessment Electrocardiogram (ECG)Echocardiogram6-minute walk distance (6MWD)Blood Work:
• ABGs• CBCs• Alpha-1 antitrypsin• Plasma cotinine• Serum fibrinogen
BASELINE ELIGIBILITY SCREENINGPulmonary Rehabilitation Eligibility Criterion CompletedSpirometry6MWDQOL Questionnaires
STUDY PROCEDURE ELIGIBILITY SCREENINGBronchoscopy procedure to assess collateral ventilation using the Chartis System
IF ASSIGNED TO STUDY TREATMENT EBV5 night hospital stay, discharge on Day 6X-ray seriesHRCT AssessmentPulmonary RehabilitationClinic Visits:
• 7 days post discharge• 30 and 45 days• 3, 6, and 9 months• 1 year• Annually at 2, 3, 4, and 5 years
IF ASSIGNED TO CONTROL ARMPulmonary RehabilitationClinic Visits:
• 45 days• 3, 6, and 9 months• 1 year
After successful completion of the 1-year visit, control arm patients may be eligible for crossover to the study treatment (EBV).
Zephyr® Endobronchial Valve Study Plan & Assessments
Place Study Site Contact Information Here
CAUTION: The Zephyr® Endobronchial Valve is an investigational device in the US, limited by US law to investigational use. Inclusion/Exclusion criteria listed above are not all inclusive – please reference study protocol.
CL069_23FEB2015
Pulmonx Corporation700 Chesapeake DriveRedwood City, CA 94063 USATel: +1 (650) [email protected]
Clinicaltrials.gov NCT01796392
JOIN US IN CREATING NEW HOPE
Pulmonx_Liberate-Phy_Brochure-PRESS.indd 2-3 4/24/15 10:42 AM
CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.
Pulmonx Corporation700 Chesapeake Drive, Redwood City, CA 94063 USATel: +1 (650) 364-0400
www.pulmonx.com
CL079_13APR2015
...a Patient Selection Tool for Personalized Treatment
Over 65% of severe emphysema patients have one or more target lobes with low collateral ventilation
10,000+ Patients Treated with Zephyr® Endobronchial Valves
Chartis® Pulmonary Assessment System
...Clinical Data Demonstrating SustainedBenefitsto5Years
Source: Hübner 2014 Source: Venuta 2012
250
300
350
400
450
Baseline
Year
1
Year
3
Year
5
6 MWT (m)
0.8
1
1.2
1.4
Baseline
Year
1
Year
3
Year
5
FEV 1 (L)
Pulmonx Offers the Only Lung Volume Reduction Therapy with...
RCT SUMMARY Design Follow-up Period
FEV1%Improvement
6 MWTImprovement
SGRQImprovement
STELVIOn = 68
1:1 RCT Valves vs. SOC
Heterogeneous & Homogeneous
6 months 22.7%* 106m* -15 pts*
BeLieVeR-HIFin = 50
1:1 RCT Valves vs. Sham Heterogeneous
3 months 20.9%* 33m -5 pts
VENT (US + OUS)
n = 492 (122 in subset)2:1 RCT
Valves vs. SOC Heterogeneous & Homogeneous
6 months 24.7%* 28m* -8.4 pts*
In all three RCTs, patient outcomes exceeded the MCID in measures of lung function, exercise capacity and quality of life.
*Statistically significant difference from controlSources: STELVIO (ATS 2015), BeLieVer-HIFi (ERS 2014), Sciurba 2010/Herth 2012, Pulmonx data on file.
900+Patients in
Clinical Trials
NEW
NEW
Pulmonx_Transform-Trial_Poster-PRESS_OTL.indd 1 6/5/15 4:44 PM
Physician Brochure
Clinical Study Sheet
Website
Trial Poster
S P R I G | 7
GROW THE COMPANY• CLINICAL MARKETING •
Clinical evidence solidifies your
position in the market. Expedite
patient enrollment. SPRIG can
help drive study enrollment with
engaging materials for patients
and physicians that incorporate
your brand and messaging.
Elixir Medical | elixirmedical.comEBR Systems | ebrsystemsinc.com
HeartFlow | heartflow.com
Fractyl | fractyl.com
Shifamed | shifamed.comPulmonx | pulmonx.com
Corvia Medical | corviamedical.com
S P R I G | 8
GROW THE COMPANY• WEBSITE DEVELOPMENT •
A website is your company’s
first impression in the market.
Make yours impactful.
SPRIG has a long track record
of transitioning corporate
identities into websites that
become effective resources.
UNIQUE Drug Agent
ClINICal Performance Sets New Standards
Advanced Drug/Polymer Coating Technology Thin polymer and drug matrix coating without the need for a primer coating
Superior DES clinical performance with excellent safety profile1
Lowest Polymer Coating Load2
Reduced risk of adverse clinical events 1
Improved polymer biocompatibility3
Low Drug Dose Sustainable performance with lower drug dose
EXCELLA II RCT (n = 210)
Proprietary Novolimus Drug Elution Established safety and performance• Clinically proven ‘olimus’ drug family• Active metabolite of Sirolimus
Proprietary drug facilitates superior clinical efficacy1
• Potent anti-proliferative agent with known safety profile
Significant reduction in late lumen loss, p = 0.001 Lowest published late lumen loss 4
Low neointimal volume obstruction
Significant reduction in CI-TLR at 2 years, p<0.05
Sustained clinical performance over time
Optimal neointimal coverage with low neointimal volume obstruction
MACE defined as target lesion revascularization, cardiac death and myocardial infarction
1 » Serruys, P.W. et. al, EuroIntervention 2010.
2 » As compared to manufacturer reported thickness for Xience V® and Resolute®. Data on file at Elixir Medical.
3 » Data on file at Elixir Medical.
4 » As compared to manufacturer reported late lumen loss at follow up from similar trials. Data on file at Elixir Medical.
5 » SIRIUS: Weisz, G. et. al., JACC 2006 ; RESOLUTE: Serruys, P.W., EuroPCR 2009 ; SPIRIT III: Stone, G. W., Circulation 2009.
ENDEAVOR® and RESOLUTE® are registered trademark of Medtronic, XIENCE V® is registered trademark of Abbott Vascular, CYPHER® is registered trademark of Cordis Corporation.
0 .6
20.0%
60.0%
0.7
12.0%
12.0%
8.0%
8.0%
4.0%
4.0%
10.0%
10.0%
6.0%
6.0%
2.0%
2.0%
25.0%
70.0%
0.114.5%
27.3%
4.9%
4.3%
0.63
20.9%
9.9%
0.5
15.0%
50.0%
0.4
5.0%
40.0%
0.3
30.0%
0 .2
20.0%
0 .1
10.0%
0
0
0
0
0
(mm
)%
%
%
%
ENDEAVOR® ENDEAVOR®
ENDEAVOR®
ENDEAVOR®
RESOLUTE® (RESOLUTE)
XIENCE V® (SPIRIT III)
CYPHER®
(SIRIUS)
late lumen loss at 9 Months Neointimal Volume Obstruction by IVUS at 9 Months
MaCE at Year 1 and Year 2 Clinical Follow-up
Neointima-free Frame Ratio (% cross-sections without neointima coverage)
Major adverse Cardiac Events (MaCE) at 2 Years Clinical Follow-up
82% reduction
56% reduction
Similar Trial results at 8-9 months5
Similar Trial results at 2 years5
78% reduction
0.17
10.3%
0.22
7.9% 7.7%
0.16XIENCE V®
7.8 µm
RESOLUTE® 5.6 µm
3 µm
Cobalt Chromium Platform Lowest profile stent design2 with ultra-thin struts (81 microns) for high flexibility and deliverability Substantial vessel wall coverage for uniform drug delivery and open cell design for ease of side branch access 4.3%
7.0%
9.9%
4.3% 5.6%
7.0%
Coating Technology
1.4% CI -TLR
Year 1 Year 2 Year 1 Year 2
1.4%
ENDEAVOR® RESOLUTE® (RESOLUTE)
XIENCE V® (SPIRIT III)
CYPHER®
(SIRIUS)
The Path to
NExT GENERaTION
DRUG ElUTING STENT
TEChNOlOGY…
Introducing the Novolimus —
eluting DESyne™ stent —
the next generation drug
eluting stent with improved
performance and superior
clinical efficacy and safety1.
Engineered on a clinically —
proven cobalt chromium
platform, the novel design
and Formula X™ drug/
polymer coating technology
allows for thin struts, lowest
polymer load2, and lowest drug
concentration2 of any DES on
the market today.
DESyne™ maximizes
deliverability and is able to
deliver superior performance
with the lowest published
late lumen loss4.
Engineered to maximize
DELIvERAbILITy &
CLINICAL PERFORMANCE
L e a d i n g t h e W a y t o n e x t g e n e r a t i o n d e S P L a t F o r M S INNOVATING VASCULAR RESTORATION™
Novolimus ElutiNg CoroNary stENt systEm
INNOVATION fOr LIfe®
NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM
introducing the DESolve Scaffold Platform
Innovating Vascular Restoration
E L I X I R M E D I C A L . C O M
Thursday 23rd May, 2013 12:00-13:30 Room 241
Chairpersons:
Faculty:
MARTIN B. LEON, MDALEXANDRE ABIZAID, MD, PHD
John Ormiston, MDStefan Verheye, MD, PHDBernhard Witzenbichler, MD
Elixir, Innovation for Life, DESyne and DESolve are registered trademarks of Elixir Medical Corporation. DESyne, DESyne BD, and DESolve CE mark approved,
international use only. MN 171 Rev A
Visit us at booth #F5 to Learn more about our complete product portfolio including the DESyne® Novolimus Eluting Coronary Stent System and DESyne®BD Novolimus Eluting Coronary Stent System
Product Brochure
Ad Campaign Product Packaging
S P R I G | 9
MARKET THE PRODUCT• COMMERCIALIZATION •
CorPath_ReferralBrochure-PRESS_2014Mar24.indd 4-5 3/24/14 1:29 PM
Booth Graphics
Product Brochure
Ad Campaign Sales SheetInfographic
S P R I G | 1 0
MARKET THE PRODUCT• COMMERCIALIZATION •
Needs for Advancement in Stroke Care
Lessons from Recent Trials
About Us
Outcomes Driven Innovation
ML010 Rev01
ClinicalSolution Action Video 1 2 3 4 5 6 7 8 9
Trap the Clot Inside
• Clot gripped inside
• Minimal compression
• Articulated design for retention
1
ML010 Rev01
1 2 3About Us Trials Needs
Compelling Positive Trials
6
"The data are consistent and convincing. We are now obligated to use this technology in eligible stroke patients with a large vessel occlusion.”
Dr. Kyra Becker, MDISC Program Chair
“This is the most significant and fundamental change in acute ischemic stroke treatment in the last 20 years. These results will impactstroke care around the world.”
Dr. Michael Hill ESCAPE Study Co-PI
"This is a once-in-a-generation advance in stroke care.”
Dr. Jeffrey Saver SWIFT PRIME PI
“Taken together, these studies willrevolutionize the way we treat ischemic stroke caused by a blockage of one of the major cerebral arteries.”
Dr. Bruce Campbell EXTEND-IA PI
1
Results presented at ISC 2015as reported by Medscape
ML010 Rev01
CardioKinetix | Product Brochure
Sapheon | Patient BrochureNeuravi | Interactive PowerPoint Presentation
Marketing and sales collateral can be
an effective tool to build awareness
and communicate the value of your
technology. Our goal is to inspire action.
With our trusted design partners, SPRIG
has created compelling materials to convey
clients’ most important messages.
UNDERSTAND
Varicose veins may be a sign of something more
severe — venous reflux disease. Your doctor can help
you understand if you have this condition.
Healthy leg veins have valves that keep blood flowing
to the heart. Venous reflux disease develops when the
valves stop working properly and allow blood to flow
backward (i.e., reflux) and pool in the lower leg veins.
If venous reflux disease is left untreated, symptoms
can worsen over time.
1 Criqui, M. H., Denenberg, J. O., Langer, R. D., Kaplan, R. M., & Fronek, A. (2013). Epidemiology of Chronic Peripheral Venous Disease. In J. J. Bergan & N. Bunke-Paquette (Eds.), The Vein Book (pp. 27-36). New York, NY: Oxford University Press.
Superficial venous reflux disease may cause the following
symptoms in your legs:1
Varicose veins
Aching
Swelling
Cramping
Heaviness or tiredness
Itching
Open skin sores
Restlessness
DISEASED VEIN Valves that cannot
close allow blood to drain and pool
NORMAL VEINValves ensure
blood flows in one direction
SUPERFICIAL VENOUS ANATOMY
COMMON FEMORAL VEIN
SMALL SAPHENOUS VEIN
GREAT SAPHENOUS VEIN
ANTERIOR ACCESSORY
GREAT SAPHENOUS VEIN
BACK FRONT
livewith relief from varicose veins
Covidien llc
951 Aviation Parkway, Suite 900 | Morrisville, NC 27560 | United States
www.covidien.com
Talk to your doctor to learn if VenaSeal™ is right for you.
MKT-11716-01 Rev A
VenaSeal is a trademark of a Covidien company. © 2015 Covidien llc
Caution: Federal law restricts this device to sale by or on the order of a physician. Please reference the Instructions For Use (IFU) for a complete listing of indications,
contraindications, warnings and precautions, adverse effects and suggested procedure. An electronic IFU can be accessed at www.useifu.venaseal.com.
Dedicated to Advancing
Neurointerventional
Therapies for Stroke
ML010 Rev01
S P R I G | 1 1
MARKET THE PRODUCT• MARKETING AND SALES COLLATERAL •
Vascular Interventional AdvancesInternational Symposium on
Endovascular Therapy
Innovations in Cardiac Interventions
Israel Advanced Technology Industries
S P R I G | 1 2
MEET WITH US SPRIG regularly attends the following conferences:
Your elite med-tech
marketing team.
PROUD SPONSOR OF THE MEDTECHVIS ION CONFERENCE
